SERES THERAPEUTICS, INC.

CAMBRIDGE, MA, 02140

Subcontracting experience

1 record from government sources. Past participation is not evidence of current teaming interest.

Role	Agency	Description	Vehicle	Obligated	Action date	Period
Subcontractor	Department of Health and Human Services	SERES IS DEVELOPING A NOVEL LIVE BIOTHERAPEUTIC PRODUCT (LBP) OF HUMAN COMMENSAL BACTERIA FORMULATED FOR ORAL LIQUID DELIVERY, TO ADDRESS THE UNMET NEED FOR PREVENTION OF GUT-SEEDED AMR INFECTION IN THE MEDICAL ICU. INFECTIONS WITH PATHOGENIC (OFTEN MULTIDRUG RESISTANT, MDR) BACTERIA ARE THE LEADING CAUSE OF MORTALITY IN THE MEDICAL INTENSIVE CARE UNIT (ICU), CAUSING UP TO 9 DEATHS FOR EVERY 100 ICU PATIENTS ADMITTED (VINCENT, 2009). MOST PATIENTS ARE ADMITTED TO THE MEDICAL ICU WITH A KNOWN OR SUSPECTED INFECTION (I.E., SEPSIS) BUT, WITH TARGETED OR EMPIRIC ANTIBIOTICS, MOST RECOVER FROM THIS INITIAL INFECTION. WHAT CAUSES DEATHS—AND WHAT THIS PROJECT PROPOSES TO PREVENT—ARE THE SECONDARY, HEALTHCARE- ASSOCIATED INFECTIONS THAT FREQUENTLY DEVELOP DURING THE PROLONGED RECOVERY FROM SEPSIS. A NOVEL APPROACH THAT ADDRESSES BOTH GUT COLONIZATION AND SUBSEQUENT TRANSLOCATION BY E. COLI AND OTHER GUT SEEDED PATHOGENS COULD PREVENT A SIGNIFICANT PROPORTION OF THESE INFECTIONS. IF GUT COLONIZATION AND TRANSLOCATION BY E. COLI COULD BE AMELIORATED BY A LBP SUCH AS SER-155, A LARGE PROPORTION OF THESE INFECTIONS COULD BE PREVENTED. SER-155 IS CURRENTLY IN CLINICAL DEVELOPMENT AND HAS BEEN EVALUATED IN ALLOGENEIC HCT PATIENTS. DATA FROM OUR PHASE 1B STUDY SUPPORTS THE SAFETY AND EFFICACY OF SER-155 IN PREVENTING INFECTION IN IMMUNE COMPROMISED, HOSPITALIZED PATIENTS. THE PROPOSED WORK WILL EXTEND THESE FINDINGS BY DEVELOPING A LIQUID FORMULATION OF SER-155 (“SER-155-LF"), A NECESSARY STEP IN THE MEDICAL ICU AS PATIENTS ARE COMMONLY INTUBATED WITH NARROW-CALIBER GASTRIC OR DUODENAL FEEDING TUBES, PLACED FOR THE DELIVERY OF MEDICATIONS AND ENTERAL NUTRITION. UPON SUCCESSFUL DEVELOPMENT OF A LIQUID FORMULATION WHICH IS SUITED FOR DELIVERY IN THE ICU VIA NG TUBE, THE PROPOSED WORK PLAN WILL NEXT FOCUS ON GMP MANUFACTURING OF SER-155-LF FOR CLINICAL STUDY AND PREPARATION OF AN EARLY PHASE TRIAL IN ICU PATIENTS WITH A PRIMARY OUTCOME OF SAFETY AND ENGRAFTMENT, EXPLORATORY ENDPOINTS AROUND E. COLI COLONIZATION AND AMR, AND DENSE DOWNSTREAM CLINICAL AND MECHANISTIC ANALYSES. KC4092 Parent award context Parent award agency: Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response Parent award NAICS: 541714 Parent award performance state: MA Parent award description: CARB-X GLOBAL ANTIBACTERIAL ACCELERATOR OTA View parent award on USAspending	—	$895,707	Sep 15, 2025	— – —

Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.

Is this your company?

Claim this profile for free to add your capabilities, teaming interests, capability statement link and employee count, and to report certifications for verification.

FedSub reviews every claim before granting access. Government-sourced data stays as published; your additions are labeled company-reported.

Claim this profile (free)

Identifiers

UEI: X7LRVD7ZXMK5
CAGE: 7V3D4

NAICS codes

541714Research and Development in Biotechnology (except Nanobiotechnology)Primary(definition)

Data sources

SAM.gov monthly extract
ID X7LRVD7ZXMK5 · fetched Oct 25, 2026 · source
USAspending.gov
ID recipient:X7LRVD7ZXMK5 · fetched Oct 26, 2026 · source

Last synced Oct 25, 2026 · profile updated Oct 25, 2026

Find similar contractors

Government-sourced data comes from SAM.gov, SBA and USAspending.gov and is attributed to its source. Items marked company-reported were provided by the company and are verified by FedSub only where labeled. FedSub is a private company and is not affiliated with SBA, GSA/SAM.gov, or any government agency.